BURLINGAME, Calif., Oct. 04, 2016 (GLOBE NEWSWIRE) — Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced that it will present preclinical data and preliminary biomarker data from its ongoing Phase 1/1b study of CPI-444 as a single agent, and in combination with Genentech’s TECENTRIQ™ (atezolizumab), in poster presentation sessions at the European Society for Medical Oncology (ESMO) 2016 Congress, which is taking place October 7-11 at the Bella Center in Copenhagen, Denmark.
The ESMO abstracts are now available at www.esmo.org. Following are details for each poster presentation.
Sunday, October 9
Abstract #: 1068P
Abstract Title: Adenosine A2A receptor antagonist, CPI-444, blocks adenosine-mediated T cell suppression and exhibits anti-tumor activity alone and in combination with anti-PD-1 and anti-PD-L1
Poster Presenter: Stephen Willingham, Ph.D., Senior Scientist, Corvus
Poster Presentation Time: 13:00-14:00 CEST
Poster Display Location: Hall E
Abstract #: 1105TiP
Abstract Title: Phase 1/1b multicenter trial of the adenosine A2a receptor antagonist (A2aR) CPI-444 as single agent and in combination with atezolizumab (ATZ) in patients (Pts) with advanced cancers
Poster Presenter: Ginna G. Laport, M.D., Vice President, Clinical Development, Corvus
Poster Presentation Time: 13:00-14:00 CEST
Poster Display Location: Hall E
Monday, October 10
Abstract #: 389P
Abstract Title: Biomarker and clinical activity of CPI-444, a novel small molecule inhibitor of A2A receptor (A2AR), in a Phase 1b study in advanced cancers
Poster Presenter: Ian McCaffery, Ph.D., Vice President, Translational Sciences, Corvus
Poster Presentation Time: 13:00-14:00 CEST
Poster Display Location: Hall E
About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of small molecule and antibody agents that target the immune system to treat patients with cancer. These agents block or modify crucial immune checkpoints and reprogram immune T-cells. Corvus’ lead product, CPI-444, is a checkpoint inhibitor that is designed to disable a tumor’s ability to subvert attack by the immune system by inhibiting adenosine in the tumor microenvironment. CPI-444 is a small molecule that is taken orally. CPI-444 is currently being evaluated in a multicenter Phase 1/1b clinical trial in patients with various solid tumors. This successive expansion cohort trial is examining the activity of CPI-444 both as a single agent and in combination with Genentech’s TECENTRIQ (atezolizumab), an anti-PD-L1 antibody. Corvus is conducting the trial with Genentech, a member of the Roche Group, under a clinical trial collaboration the two companies entered into in October 2015. For more information, visit: www.corvuspharma.com.
CONTACT: Investor Contact: Jason Coloma, Ph.D. SVP and Chief Business Officer 650-900-4511 JColoma@corvuspharma.com Media Contact: Julie Normart, W2O Group 415-946-1087 jnormart@w2ogroup.com
